DOI: http://dx.doi.org/10.18203/2319-2003.ijbcp20211649

A rational pharmacotherapeutic study of the prevalent prescription patterns of delamanid, ofloxacin, levofloxacin, and bedaquiline among the multi-drug resistant tuberculosis patients in global multi-centre tertiary care hospitals

Moumita Hazra

Abstract


Background: Delamanid, a nitro-dihydro-imidazooxazole, is a bactericidal cell wall methoxy-mycolic and keto-mycolic acids biosynthesis inhibitor in actively replicating, dormant, and intracellular tuberculosis, and both drug-susceptible and drug-resistant strains of M. tuberculosis and M. kansasii, decreasing hydrophobicity and facilitating better bacterial drug penetration. Delamanid promotes intracellular generation of microbiocidal nitrogen oxidative intermediaries including nitric oxide, toxic even to dormant M. tuberculosis. Ofloxacin, the racemic mixture and levofloxacin, the S-or levorotatory isomer of ofloxacin, are bactericidal to M. tuberculosis, MAC, M. fortuitum, and other atypical mycobacteria, with inhibitory effect on DNA gyrase, DNA topoisomerase IV and IL-1α, IL-6, IL-8. Bedaquiline, a novel diarylquinoline, inhibits mycobacterial adenosine triphosphate synthase of M. tuberculosis, disrupting mycobacterial energy metabolism and replication. Bedaquiline’s initial bacteriostatic action is followed by a bactericidal effect after 5-7 days. The objective was to perform a rational pharmacotherapeutic study of the prevalent prescription patterns of delamanid, ofloxacin, levofloxacin, and bedaquiline, among the multi-drug resistant tuberculosis patients, in global multi-centre tertiary care hospitals.

Methods: A multi-centre, retrospective, observational and analytical study of clinical prescriptions of 100 multi-drug resistant tuberculosis patients in hospitals, were performed. For 24-48 weeks, these patients had been prescribed anti-tubercular drugs, like delamanid 100 mg and ofloxacin 400 mg twice daily, levofloxacin 750 mg and bedaquiline 400 mg once daily followed by 200 mg thrice weekly, as part of MDR-TB treatment regimens. The no. of prescriptions for each drug were recorded, and the corresponding prescription rates were statistically derived in percentages.

Results: Delamanid was most commonly prescribed (32 prescriptions, 32%), followed by ofloxacin (29 prescriptions, 29%), levofloxacin (24 prescriptions, 24%), and bedaquiline (15 prescriptions, 15%). The completeness of the prescription contents, the dose of drug, the duration of treatment, the instructions of medication, the frequency of drug intake, the name of the drug and the dosage form of the drug were observed in 100% of prescriptions.

Conclusions: Prescription frequency of delamanid was followed by ofloxacin, levofloxacin and bedaquiline. Prescription content analyses showed 100% completeness.


Keywords


Prescription patterns, Delamanid, Ofloxacin, Levofloxacin, Bedaquiline, Multi drug-resistant tuberculosis

Full Text:

PDF

References


Falzon D, Schünemann HJ, Harausz E, González-Angulo L, Lienhardt C, Jaramillo E et al. World Health Organization treatment guidelines for drug-resistant tuberculosis, 2016 update. Eur Respir J. 2017;49:1602308.

D'Ambrosio L, Centis R, Sotgiu G, Pontali E, Spanevello A, Migliori GB. New anti-tuberculosis drugs and regimens: 2015 update. ERJ Open Res. 2015;1(1):00010-2015.

Pontali E, Sotgiu G, Tiberi S, Tadolini M, Visca D, D’Ambrosio L et al. Combined treatment of drug-resistant tuberculosis with bedaquiline and delamanid: a systematic review. Eur Respir J. 2018;52:1800934.

Sapkal PM, Pantwalawalkar JR. Tuberculosis drug resistance: an overview. Int J Res Methodol. 2015;1(2):8-18.

Field SK. Safety and efficacy of delamanid in the treatment of multidrug-resistant tuberculosis (MDR-TB). Clin Med Insights Ther. 2013;5:137-49.

Chang KC, Yew WW. Management of difficult multidrug‐resistant tuberculosis and extensively drug‐resistant tuberculosis: Update 2012. Respirology. 2013;18(1):8-21.

Tiberi S, Scardigli A, Centis R, D’Ambrosio L, Muñoz-Torrico M, Salazar-Lezama MÁ et al. Classifying new anti-tuberculosis drugs: rationale and future perspectives. Int J Infect Dis. 2017;56:181-4.

Migliori GB, Tiberi S, Zumla A, Petersen E, Chakaya JM, Wesje C et al. MDR/XDR-TB management of patients and contacts: challenges facing the new decade. The 2020 clinical update by the Global Tuberculosis Network. Int J Infect Dis. 2020;92S:S15-25.

Gupta R, Wells CD, Hittel N, Hafkin J, Geiter LJ. Delamanid in the treatment of multidrug-resistant tuberculosis. Int J Tuberc Lung Dis. 2016;20(12):S33-7.

Santiago MR, Garfin AMC, Balanag VM. Introduction of bedaquiline for the treatment of drug-resistant TB in the Philippines. Int J Tuberc Lung Dis. 2020;24(10):1063-6.

Sotgiu G, D’Ambrosio L, Centis R, Mura I, Castiglia P, Spanevello A et al. The multidrug-resistant tuberculosis threat: old problems and new solutions. J Thorac Dis. 2015;7(9):E354-60.

Mohammed HHH, Abuo-Rahma GEAA, Abbas SH, Abdelhafez EMN. Current trends and future directions of fluoroquinolones. Curr Med Chem. 2019;26(17):3132-49.

Nahid P, Mase SR, Miglior GB, Sotgiu G, Bothamley GH, Brozek JL et al. Treatment of drug-resistant tuberculosis. An official ATS/CDC/ERS/IDSA Clinical Practice Guideline. Am J Respir Crit Care Med 2020;201:500-01.

World Health Organization. 2020. Global tuberculosis report, 2020. Available from: https://www.who.int/teams/global-tuberculosis-programme/tb-reports. Accessed on Feb 2020.

Bonnet M, Bastard M, Du Cros P, Khamraev A, Kimenye K, Khurkhumal S et al. Identification of patients who could benefit from bedaquiline or delamanid: a multisite MDR-TB cohort study. Int J Tuberc Lung Dis 2015;20(2):177-86.

Xavier AS, Lakshmanan M. Delamanid: a new armor in combating drug resistant tuberculosis. J Pharmacol Pharmacother. 2014;5(3):222-4.

Upton AM, Cho S, Yang TJ, Kim Y, Wang Y, Lu Y et al. In vitro and in vivo activities of the nitroimidazole TBA-354 against Mycobacterium tuberculosis. Antimicrob Agents Chemother. 2015;59(1):136-44.

Liu Y, Hafkin J. Delamanid: from discovery to its use for pulmonary multidrug-resistant tuberculosis (MDR-TB). Tuberculosis. 2018;111:20-30.

Das S, Sehgal VK. Delamanid and its role in drug-resistant tuberculosis. Int J Med and Dent Sci. 2017;6(1):1449-53.

Sloan DJ, Lewis JM. Management of multidrug-resistant TB: novel treatments and their expansion to low resource settings. Trans R Soc Trop Med Hyg. 2016;110:163-72.

Rustomjee R, Zumla A. Delamanid expanded access novel treatment of drug resistant tuberculosis. Infect Drug Resist. 2015;8:359-66.

Brigden G, Hewison C, Varaine F. New developments in the treatment of drug resistant tuberculosis: clinical utility of bedaquiline and delamanid. Infect Drug Resist. 2015;8:367-78.

Hazra M. A multivariate comparative clinical pharmacotherapeutic efficacy and chrono-pharmacovigilance assessment study of ofloxacin, one of the commonplace TGFβ1 inducing and telomerase impairing fluoroquinolones, in treating acute gastroenteritis, chronic obstructive pulmonary disease, new drug-sensitive tuberculosis, recurrent mixed cutaneous infections, and post-surgical refractory wound infections, among the global patients, with heterogenous pharmaco-geographic and pharmacogenomic constitution. Int J Basic Clin Pharmacol. 2021;10(3):270-80.

Karampela I, Dalamaga M. Could respiratory fluoroquinolones, levofloxacin and moxifloxacin, prove to be beneficial as an adjunct treatment in COVID-19? Arch Med Res. 2020;51(7):741-2.

Brar RK, Jyoti U, Patil RK, Patil HC. Fluoroquinolone antibiotics: an overview. Adesh Univ J Med Sci Res. 2020;2(1):26-30.

World Health Organization. 2020. Differences among fluoroquinolones in the treatment of MDR-TB. Available from: https://www.archives.who.int. Accessed on 20 Dec 2020.

Tripathi KD. Antitubercular Drugs. In: Tripathi M, ed. Essentials of Medical Pharmacology. 7th ed. New Delhi, London, Philadelphia, Panama: Jaypee Brothers Medical Publishers Ltd. 2013;765-79.

Gumbo T. Chemotherapy of tuberculosis, Mycobacterium avium complex disease, and leprosy. In: Brunton LB, Hilal-Dandan R, Knollmann BC, eds. Goodman and Gilman's The Pharmacological Basis of Therapeutics. 13th ed. New York, Chicago, San Francisco, Athens, London, Madrid, Mexico City, Milan, New Delhi, Singapore, Sydney, Toronto: McGraw-Hill. 2018;1067-86.

Xu Z, Zhao SJ, Lv ZS, Gao F, Wang Y, Zhang F et al. Fluoroquinolone-isatin hybrids and their biological activities. Eur J Med Chem. 2019;162:396-406.

Diel R, Vandeputte J, de Vries G, Stillo J, Wanlin M, Nienhaus A. Costs of tuberculosis disease in the European Union: a systematic analysis and cost calculation. Eur Respir J. 2014;43:554-65.